546 related articles for article (PubMed ID: 23964098)
1. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy.
Stegeman I; de Wijkerslooth TR; Stoop EM; van Leerdam ME; Dekker E; van Ballegooijen M; Kuipers EJ; Fockens P; Kraaijenhagen RA; Bossuyt PM
Gut; 2014 Mar; 63(3):466-71. PubMed ID: 23964098
[TBL] [Abstract][Full Text] [Related]
2. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
3. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
4. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
[TBL] [Abstract][Full Text] [Related]
5. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer.
Stegeman I; de Wijkerslooth TR; Stoop EM; van Leerdam ME; Dekker E; van Ballegooijen M; Kuipers EJ; Fockens P; Kraaijenhagen RA; Bossuyt PM
Cancer Epidemiol; 2013 Jun; 37(3):278-83. PubMed ID: 23491770
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme.
van de Veerdonk W; Van Hal G; Peeters M; De Brabander I; Silversmit G; Hoeck S
Cancer Epidemiol; 2018 Oct; 56():90-96. PubMed ID: 30114631
[TBL] [Abstract][Full Text] [Related]
8. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
Kelley L; Swan N; Hughes DJ
Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
[TBL] [Abstract][Full Text] [Related]
9. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
10. Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.
Cooper JA; Parsons N; Stinton C; Mathews C; Smith S; Halloran SP; Moss S; Taylor-Phillips S
Br J Cancer; 2018 Jan; 118(2):285-293. PubMed ID: 29096402
[TBL] [Abstract][Full Text] [Related]
11. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
[TBL] [Abstract][Full Text] [Related]
12. A validated tool of combining risk factors with fecal immunochemical test for selecting colonoscopy in asymptomatic Chinese population.
Liao Y; Li S; Chen H; Chen C; Huang J; Lin F; Wang J; Yang Z
Eur J Cancer Prev; 2023 May; 32(3):275-280. PubMed ID: 32925509
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
[TBL] [Abstract][Full Text] [Related]
14. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
15. Offering people a choice for colorectal cancer screening.
Senore C; Ederle A; Benazzato L; Arrigoni A; Silvani M; Fantin A; Fracchia M; Armaroli P; Segnan N
Gut; 2013 May; 62(5):735-40. PubMed ID: 22442162
[TBL] [Abstract][Full Text] [Related]
16. Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys.
Wong MC; John GK; Hirai HW; Lam TY; Luk AK; Ching JY; Ng SS; Chan FK; Griffiths SM; Sung JJ
Cancer Causes Control; 2012 Sep; 23(9):1541-8. PubMed ID: 22836914
[TBL] [Abstract][Full Text] [Related]
17. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
[TBL] [Abstract][Full Text] [Related]
18. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
19. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria.
Cubiella J; Salve M; Díaz-Ondina M; Vega P; Alves MT; Iglesias F; Sánchez E; Macía P; Blanco I; Bujanda L; Fernández-Seara J
Colorectal Dis; 2014 Aug; 16(8):O273-82. PubMed ID: 24456168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
